Biosimilars – From An Executive Perspective

An interview with executive Ian Henshaw – By Jonas Mortensen, CEO, BioBridge Solutions

Biosimilars have evolved from a perceived niche into one of the most disruptive forces in global healthcare. This interview offers an executive‑level perspective on how the sector has matured—and where it is headed next.

Drawing on decades of leadership across innovative and follow‑on medicines, the conversation explores early misconceptions about biosimilars, the realities of price pressure, and why manufacturing excellence and supply reliability now matter as much as scientific comparability. The discussion highlights biosimilars as a true “scale game,” where cell line productivity, cost of goods, and integrated platforms can determine long‑term success or failure.

Beyond operations, the preview examines commercial strategy, tender dynamics, and the growing expectation from healthcare systems for uninterrupted patient access. Looking ahead, it addresses consolidation, partnerships, continuous manufacturing, and sustainability over a product’s full lifecycle.

The result is a grounded, forward‑looking view of a market moving rapidly from opportunity to necessity—reshaping access, affordability, and competition in biologic medicines worldwide.